Ifabotuzumab KB004|cas:2147698-66-4|西域试剂

Ifabotuzumab KB004,95.0%

产品编号：Bellancom-P99655| CAS NO：2147698-66-4

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P99655	￥3000.00	杭州北京（现货）
Bellancom-P99655	￥7400.00	杭州北京（现货）
Bellancom-P99655	￥12000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Ifabotuzumab KB004

产品介绍

Ifabotuzumab (KB004) 是靶向 EphA3 的 IgG1κ 抗体 (K_D=610 pM)。Ifabotuzumab 能够导致肿瘤细胞凋亡，并激活抗体依赖性细胞介导的细胞毒作用 (ADCC)，破坏肿瘤脉管系统。Ifabotuzumab 能够减少人特发性肺纤维化 (IPF) CCR10⁺ 细胞，改善肺纤维化。

生物活性

Ifabotuzumab (KB004) is an IgG1κ antibody targeting EphA3 (K_D=610 pM). Ifabotuzumab induces tumor cell apoptosis, activates Antibody-dependent cell mediated cytotoxicity (ADCC), and damages tumor vasculature. Ifabotuzumab reduces human idiopathic pulmonary fibrosis (IPF) CCR10⁺ cells and improves pulmonary fibrosis.

体外研究

体内研究

Ifabotuzumab (5 mg/kg; 腹腔注射; 每周 2 次, 共 5 周) 在肺纤维化人源小鼠模型中具有改善作用。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Humanized NSG mice with lung fibrosis
Dosage:	5 mg/kg
Administration:	Intraperitoneal injection; twice weekly for 5 weeks
Result:	Significantly reduced hydroxyproline to levels and IL-6 transcript levels. Significantly reduced the total number of CCR10⁺EphA3⁺, as well as Lin^-CCR10⁺ cells.

体内研究

Ifabotuzumab (5 mg/kg; 腹腔注射; 每周 2 次, 共 5 周) 在肺纤维化人源小鼠模型中具有改善作用。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Humanized NSG mice with lung fibrosis
Dosage:	5 mg/kg
Administration:	Intraperitoneal injection; twice weekly for 5 weeks
Result:	Significantly reduced hydroxyproline to levels and IL-6 transcript levels. Significantly reduced the total number of CCR10⁺EphA3⁺, as well as Lin^-CCR10⁺ cells.